Washington, DC 20549






ProPhase Labs, Inc.

 (Name of Issuer)


Common Stock, par value $0.0005 per share

 (Title of Class of Securities)


74345W 10 8

 (CUSIP Number)


Herbert Kozlov, Esq.

Reed Smith LLP

599 Lexington Avenue

New York, New York 10022

(212) 521-5400


(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 23, 2014


(Date of Event which Requires Filing of this Statement)



If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o



CUSIP No: 74345W 10 8


1. Name of Reporting Person:  
  Ted Karkus  
2. Check the Appropriate Box if a Member of a Group  
  (See Instructions):  
    (a)  o
    (b)  o
3. SEC Use Only  
4. Source of Funds (See Instructions) PF
5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  
6. Citizenship or Place of Organization United States


Number of



Owned by



Person with

7. Sole Voting Power 2,464,588
8. Shared Voting Power 0
9. Sole Dispositive Power 2,464,588
10. Shared Dispositive Power 0


11. Aggregate Amount Beneficially Owned by Each Reporting Person  
  2,464,588 shares of common stock  
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  
13. Percent of Class Represented by Amount in Row (11) 15.2%
14. Type of Reporting Person (See Instructions) IN




Introductory Note:


This Amendment No. 4 amends and supplements the Statement on Schedule 13D filed by Ted Karkus (the “Reporting Person”) on April 27, 2011 (the “Original Schedule 13D”, as amended and supplemented by the Schedule 13D/A filed on November 15, 2011, Amendment No. 2 filed December 14, 2011, and Amendment No. 3 filed on May 18, 2012, together with this Amendment No. 4, the “Schedule 13D”) to the extent specifically set forth below. Except as otherwise indicated, capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Schedule 13D.


Item 3. Source and Amount of Funds or Other Consideration.


Item 3 of the Schedule 13D is amended and supplemented by adding the following after the last paragraph thereof:


The Reporting Person acquired 50,000 shares of Common Stock pursuant to an award agreement between the Issuer and the Reporting Person, dated as of December 19, 2013. The Reporting Person acquired options to purchase 100,000 shares of the Issuer’s Common Stock that will vest in two annual installments beginning December 19, 2014, pursuant to a stock option award agreement between the Issuer and the Reporting Person, dated as of December 19, 2013.


The Reporting Person acquired 500,000 shares of Common Stock in open market transactions on the Nasdaq Global Market during the period June 23 2014, June 24, 2014, and June 25, 2014 for aggregate consideration of $780,191 (exclusive of commissions) as previously reported on Form 4 filed on June 26, 2014. All of the purchases were made with the Reporting Person’s personal funds.


Effective September 4, 2014, ProPhase Labs, Inc. (the “Company”) consummated a global settlement agreement with certain parties whereby, among other provisions, the Company ultimately received 3,896,264 of its common stock back into its treasury effective September 19, 2014. As a consequence of the Company’s action to acquire treasury stock, the Company’s number of shares outstanding declined to 15,902,949 and therefore increased the Reporting Person’s percentage of ownership in the Company.


Item 5. Interest in Securities of the Issuer.


Item 5 of the Schedule 13D is amended and restated in its entirety to read as follows:


(a)-(b) The Reporting Person may be deemed to beneficially own 2,464,588 shares of Common Stock. Based on 15,902,949 shares of Common Stock outstanding as of September 19, 2014, such ownership represents 15.2% of the issued and outstanding shares of the Issuer.


The Reporting Person has (i) sole power to vote 2,464,588 shares of Common Stock which is comprised of 2,164,588 shares and options to purchase 300,000 shares that are vested and exercisable as of September 19, 2014. Such amounts do not include options to purchase 400,000 shares of Common Stock that will not vest within 60 days and therefore are not exercisable within 60 days of the date hereof.


(c) The information included in Item 3 is hereby incorporated by reference. Other than the transactions described in Item 3, the Reporting Person has not engaged in any transaction in the Common Stock during the last 60 days


(d)-(e) Not applicable.






After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.



Dated: September 19, 2014


  By: /s/ Ted Karkus